Key result
Fetal variants of tenascin-C are re-expressed during pathologic cardiac tissue remodeling, making them promising novel biomarkers for diagnosis, prognosis, and targeted therapy in cardiovascular diseases.
Fetal variants of tenascin-C are re-expressed in diseased myocardium and may serve as novel biomarkers for diagnosis, prognosis, and targets for directed therapy in cardiovascular remodeling.
Should not yet change practice in cardiac remodeling; leaves open prospective validation of tenascin-C variants as biomarkers.
Fetal variants of tenascin-C are not expressed in healthy adult myocardium. But, there is a relevant re-occurrence during pathologic cardiac tissue and vascular remodeling. Thus, these molecules, in particular B and C domain containing tenascin-C, might qualify as promising novel biomarkers for diagnosis and prognosis estimation. Since a stable extracellular deposition of fetal tenascin-C variants is present in diseased cardiac tissue, the molecules are excellent target structures for antibody-based delivery of diagnostic (e.g., radionuclides) or therapeutic (bioactive payloads) agents directly to the site of disease. Against the background that fetal tenascin-C variants are functionally involved in cardiovascular tissue remodeling, therapeutic functional blocking strategies could be experimentally tested in the future.
No takes yet. Share an insight, caveat, or question.
Franz et al. (2015) conducted a review in Cardiovascular diseases. Tenascin-C was evaluated. Fetal variants of tenascin-C are re-expressed during pathologic cardiac tissue remodeling, making them promising novel biomarkers for diagnosis, prognosis, and targeted therapy in cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: